Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Reviews Microbiology

• Publication date

  2015-12-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrmicro.2015.2PMID 26639777
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of dengue vaccines

  2018cited by this paper
• Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial

  2017cited by this paper
• Preventing dengue--is the possibility now a reality?

  2015cited by this paper
• Efficacy of a tetravalent dengue vaccine in children in Latin America.

  2015cited by this paper
• Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

  2015cited by this paper
• CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice

  2015cited by this paper
• Virus-specific T lymphocytes home to the skin during natural dengue infection

  2015cited by this paper
• Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America.

  2015cited by this paper
• An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques

  2015cited by this paper
• Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

  2015cited by this paper
• Epidemiological Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus Infections

  2014cited by this paper
• A neighborhood watch upholds local immune protection

  2014cited by this paper
• A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand.

  2014cited by this paper
• Dengue Serotype Cross-Reactive, Anti-E Protein Antibodies Confound Specific Immune Memory for 1 Year after Infection

  2014cited by this paper
• On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.

  2014cited by this paper
• Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

  2014cited by this paper
• Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

  2014cited by this paper
• CD8+ T Cells Prevent Antigen-Induced Antibody-Dependent Enhancement of Dengue Disease in Mice

  2014cited by this paper
• Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones

  2014cited by this paper
• Innate immunity to dengue virus infection and subversion of antiviral responses.

  2014cited by this paper
• Vaccine-Induced Measles Virus-Specific T Cells Do Not Prevent Infection or Disease but Facilitate Subsequent Clearance of Viral RNA

  2014cited by this paper
• Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico

  2014cited by this paper
• Review article: Research on dengue during World War II revisited.

  2014cited by this paper
• High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection

  2013cited by this paper
• Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore

  2013cited by this paper
• Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity

  2013cited by this paper
• Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds: A Randomized, Controlled, Phase II Trial in Latin America

  2013cited by this paper
• The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein

  2013cited by this paper
• Reduced risk of disease during postsecondary dengue virus infections.

  2013cited by this paper
• Genetic Variants of MICB and PLCE1 and Associations with Non-Severe Dengue

  2013cited by this paper
• Role of Humoral versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate

  2013cited by this paper
• Analysis of Cross-Reactive Antibodies Recognizing the Fusion Loop of Envelope Protein and Correlation with Neutralizing Antibody Titers in Nicaraguan Dengue Cases

  2013cited by this paper
• Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

  2013cited by this paper
• Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year

  2013cited by this paper
• The global distribution and burden of dengue

  2013cited by this paper
• Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells

  2012cited by this paper
• Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

  2012cited by this paper
• Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans

  2012cited by this paper
• Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

  2012cited by this paper
• Immune response to dengue virus and prospects for a vaccine.

  2011cited by this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cited by this paper
• Faculty Opinions recommendation of Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

  2011cited by this paper
• Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains.

  2011cited by this paper
• Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

  2011cited by this paper
• Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity

  2011cited by this paper
• Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

  2011cited by this paper
• Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.

  2011cited by this paper
• Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

  2011cited by this paper
• The development of Dengue vaccines. Introduction.

  2011cited by this paper
• Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

  2011cited by this paper
• B-cell responses during primary and secondary dengue virus infections in humans.

  2011cited by this paper
• Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.

  2011cited by this paper
• Determinants of Inapparent and Symptomatic Dengue Infection in a Prospective Study of Primary School Children in Kamphaeng Phet, Thailand

  2011cited by this paper
• A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

  2010cited by this paper
• Dengue: a continuing global threat

  2010cited by this paper
• HLA and other gene associations with dengue disease severity.

  2010cited by this paper
• Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood.

  2009cited by this paper
• Evaluation of interferences between dengue vaccine serotypes in a monkey model.

  2009cited by this paper
• Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.

  2008cited by this paper
• Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4.

  2007cited by this paper
• Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

  2007cited by this paper
• Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

  2004cited by this paper
• Dengue viral infections

  2004cited by this paper
• Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates

  2004cited by this paper
• Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?

  2000cited by this paper
• Sensitivity, specificity, and vaccine efficacy.

  1998cited by this paper
• Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.

  1991cited by this paper
• Research on dengue during World War II.

  1952cited by this paper

• The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

  2026cites this paper
• Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines

  2025cites this paper
• Human T Cell Responses to Flavivirus Vaccines

  2025cites this paper
• Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections

  2025cites this paper
• Dengue Fever Vaccines: Progress and Challenges.

  2025cites this paper
• Recommendations for dengue vaccine implementation in the elderly population

  2025influential citation
• Natural Compounds and Their Analogs as Antivirals Against Dengue Virus: A Review

  2024cites this paper
• YF17D‐based vaccines – standing on the shoulders of a giant

  2024cites this paper
• A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health

  2024cites this paper
• Des vaccins contre la dengue imparfaits mais indispensables

  2024cites this paper
• Is new dengue vaccine efficacy data a relief or cause for concern?

  2023cites this paper
• Stability of Dengue 2 Nonstructural Glycoprotein 1 (NS1) Is Affected by the Nature of Basic Residue at Position NS1-324

  2023cites this paper
• Computer-aided identification of dengue virus NS2B/NS3 protease inhibitors: an integrated molecular modelling approach for screening of phytochemicals

  2023cites this paper
• Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice

  2023cites this paper
• Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice

  2023cites this paper
• Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model

  2022cites this paper
• Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach

  2022cites this paper
• Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults

  2022cites this paper
• Dengue: Vaccinesat a glance

  2022cites this paper
• In Silico Comparative Analysis of Predicted B Cell Epitopes against Dengue Virus (Serotypes 1–4) Isolated from the Philippines

  2022cites this paper
• Dengue: A Growing Problem With New Interventions.

  2022cites this paper
• Tetravalent formulation of polymeric nanoparticle-based vaccine induces a potent immune response against dengue virus.

  2022cites this paper
• Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins

  2021cites this paper
• Updates on Dengue Vaccine and Antiviral: Where Are We Heading?

  2021cites this paper
• Introduction to Flaviviruses and Their Global Prevalence

  2021cites this paper
• Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine

  2021cites this paper
• Implications of Dengue Virus Maturation on Vaccine Induced Humoral Immunity in Mice

  2021cites this paper
• Challenges Against DENV3 Vaccines: A Bioinformatic Approach

  2021cites this paper
• Comparable Accuracies of Nonstructural Protein 1- and Envelope Protein-Based Enzyme-Linked Immunosorbent Assays in Detecting Anti-Dengue Immunoglobulin G Antibodies

  2021cites this paper
• Instability of the NS1 Glycoprotein from La Reunion 2018 Dengue 2 Virus (Cosmopolitan-1 Genotype) in Huh7 Cells Is Due to Lysine Residues on Positions 272 and 324

  2021cites this paper
• Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys.

  2021cites this paper
• Viral Toxin ns1 as Pivotal Target in Development of Efficient Dengue Vaccine

  2021cites this paper
• Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand

  2021cites this paper
• Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity

  2020cites this paper
• Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines.

  2020cites this paper
• Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.

  2020cites this paper
• Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.

  2020cites this paper
• Label-Free Electrochemical Biosensors for the Determination of Flaviviruses: Dengue, Zika, and Japanese Encephalitis

  2020cites this paper
• Kinetics of CD4+ T Helper and CD8+ Effector T Cell Responses in Acute Dengue Patients

  2020cites this paper
• Dengue: current state one year before WHO 2010–2020 goals

  2020cites this paper
• Optimization of Recombinant Flavivirus Antigens for Infection Serology: Towards Syndrome-Based Multiplex Tests

  2020cites this paper
• Multifunctional T cell response in convalescent patients two years after ZIKV infection

  2020cites this paper
• Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

  2020cites this paper
• Ethics of a partially effective dengue vaccine: Lessons from the Philippines

  2020cites this paper
• Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?

  2020cites this paper
• Anti-dengue Vaccines: From Development to Clinical Trials

  2020cites this paper
• Arboviruses: A global public health threat

  2020cites this paper
• When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?

  2020cites this paper
• Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control.

  2020cites this paper
• The Potential of Biologically Active Brazilian Plant Species as a Strategy to Search for Molecular Models for Mosquito Control

  2020cites this paper
• Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine

  2020cites this paper
• Dengue Vaccine, A Double-Edged Sword.

  2020cites this paper
• Topology, Antiviral Functional Residues and Mechanism of IFITM1

  2020cites this paper
• Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes

  2019cites this paper
• Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review

  2019cites this paper
• Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.

  2019cites this paper
• Next generation designer virus-like particle vaccines for dengue

  2019cites this paper
• Dengue vaccine development: Global and Indian scenarios.

  2019cites this paper
• Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus

  2019cites this paper
• Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity

  2019cites this paper
• Focused dengue vaccine development: outwitting nature's design.

  2019cites this paper
• Dengue vaccine clinical trials in India - An opportunity to inform the global response to a re-emerging disease challenge.

  2019cites this paper
• An agent-based model of dengue virus transmission shows how uncertainty about breakthrough infections influences vaccination impact projections

  2019cites this paper
• Serostatus testing and dengue vaccine cost–benefit thresholds

  2019cites this paper
• Title Effectiveness of a novel long lasting pyriproxyfen larvicide ( SumiLarv ® 2 MR ) against Aedes mosquitoes in schools in Yangon

  2019cites this paper
• Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

  2019cites this paper
• Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development

  2019cites this paper
• Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?

  2019cites this paper
• Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand

  2019cites this paper
• A review of Dengvaxia®: development to deployment

  2019cites this paper
• Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning

  2018cites this paper
• Dengue: a growing threat requiring vaccine development for disease prevention

  2018cites this paper
• Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

  2018cites this paper
• Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype

  2018cites this paper
• Ocular Manifestations of Emerging Flaviviruses and the Blood-Retinal Barrier

  2018cites this paper
• Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody

  2018cites this paper
• The immune response against flaviviruses

  2018cites this paper
• Insights from direct studies on human dengue infections

  2018cites this paper
• Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

  2018influential citation
• Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants

  2018cites this paper
• Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach

  2018cites this paper
• THE HUMAN ANTIBODY RESPONSE TO DENV2 INFECTION AND VACCINATION

  2018influential citation
• Controversy and debate on dengue vaccine series-paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.

  2018cites this paper
• Overview of Dengue and Dengvaxia®—Optimising the use of Dengvaxia® in clinical practice

  2018cites this paper
• Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.

  2018cites this paper
• Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

  2018cites this paper
• Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes

  2018cites this paper
• C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-γ-producing T-cell responses in a mucosal dengue vaccine model.

  2018cites this paper
• The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy.

  2018cites this paper
• Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

  2018cites this paper
• A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus

  2018cites this paper
• Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine

  2018cites this paper
• An epitope-resurfaced virus-like particle can induce broad neutralizing antibody against four serotypes of dengue virus

  2018cites this paper
• Effectiveness of a novel long-lasting pyriproxyfen larvicide (SumiLarv®2MR) against Aedes mosquitoes in schools in Yangon, Myanmar

  2018cites this paper
• An agent-based model of dengue virus transmission shows how multiple uncertainties about vaccine efficacy influence public health impact projections

  2018cites this paper
• Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

  2018influential citation
• Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine

  2018cites this paper
• A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

  2018cites this paper
• Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

  2018cites this paper
• Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

  2018cites this paper